



Diabetes & OSA:

Birds of a Feather

1

Renaë Dorrity MD, FAAFP

- Sleep Medicine Physician
- Hoskinson Health and Wellness Clinic

- No disclosures

2

Notice of Requirements for Successful Completion:

Learners must participate in the full activity and complete the evaluation in order to claim continuing education credit/hours.

Presenter(s) Conflicts of Interest/Financial Relationships Disclosures:

Renaë Dorrity MD, FAAFP – None

Disclosure of Relevant Financial Relationships and Mechanism to Identify and Mitigate Conflicts of Interest: No conflicts of interest

Non-Endorsement of Products: Accredited status does not imply endorsement by ADCES or Joint Accreditation of any commercial products displayed in conjunction with this educational activity

Off-label Use: NONE

3

Diabetes Mellitus Type 2 & Obstructive Sleep Apnea

- OSA increases risk of DM2
- DM2 increases risk of OSA

4

Goals:

- Better understanding of sleep and obstructive sleep apnea
 - Understand how obstructive sleep apnea (OSA) increases risk of diabetes mellitus type 2 (DM2)
 - Understand how DM2 increases risk of OSA
 - Understand how treating OSA benefits DM2
 - Understand how DM2 treatment can impact OSA
-

5




6



Sleep

- Wake
 - Fall asleep in 20-30 minutes
 - 20-30 minutes throughout the night is normal
- Stage N1: 5%
 - Drowsiness/Light sleep
 - May not perceive as sleep
- Stage N2: 45-50%
 - Light Sleep
- Stage N3: 20-25%
 - Slow Wave Deep Sleep
 - First half of night
 - Decreases with age
- Stage REM: 20-25%
 - "Rapid Eye Movement"
 - Dream Sleep
 - First REM 90-120 minutes
 - Second half of night

7



Hypnogram

8



How Much Sleep Do I Need?



9



Sleep-Related Breathing Disorders

10

Sleep-Related Breathing Disorders


- Obstructive Sleep Apnea
- Central Sleep Apnea
- Sleep-Related Hypoventilation
- Sleep-Related Hypoxemia
- Snoring
- Catathrenia

ICSD-3-TR

11

Sleep Related Breathing Disorders

- Obstructive Sleep Apnea
- Central Sleep Apnea
- Sleep-Related Hypoventilation
- Sleep-Related Hypoxemia



J Am Coll Cardiol. 2013 Aug 13;62(7):569-76

12

Obstructive Sleep Apnea Screening

- Snoring
- Excessive Daytime Sleepiness/Tired
- Observed Apneas
- Hypertension/Elevated Blood Pressure
- Body Mass Index ≥ 35 kg/m²
- Age ≥ 50 years
- Neck Circumference $\geq 17/15$ inches
- Male Gender

13


Obstructive Sleep Apnea Signs and Symptoms

- Waking gasping/short of breath
- Mouth breathing
- Nocturia
- Morning headaches
- Insomnia
- Restless sleep
- Bruxism/teeth grinding
- Gastroesophageal reflux

14

Obstructive Sleep Apnea

- Anatomical factors
- Impaired pharyngeal dilator muscle function
- Premature awakening to mild airway narrowing (low respiratory arousal threshold)
- Unstable control of breathing (high loop gain)



Nat Sci Sleep. 2018 Jan 23;10:21-34

15



Anatomical Factors


JAMA. 2013;310(7):731-741

16

Promotion of airway collapse

Negative pressure on inspiration

Extraluminal positive pressure
Fat deposition
Small mandible




Promotion of airway patency

Pharyngeal dilator muscle contraction (genioglossus)

Lung volume (longitudinal traction)


Pharyngeal Dilators

17



Arousal Threshold

18



High Loop Gain


19

Diagnosis




20

Polysomnogram




21

Home Sleep Tests



22





23

Apnea-Hypopnea Index

- AHI
- # Apneas + # Hypopneas/Total Sleep Time
- 10 events + 40 events/5 hr = 10 events/hr
- Normal
 - 0-5 events/hr
- Mild Obstructive Sleep Apnea
 - 5-15 events/hr
- Moderate Obstructive Sleep Apnea
 - 15-30 events/hr
- Severe Obstructive Sleep Apnea
 - 30+ events/hr

24

AHI versus Hypoxic Burden



25

Adverse Effects of OSA

- Intermittent Hypoxia
- Intermittent Hypercapnia
- Cortical Microarousals
- Increased Oxidative Stress
- Inflammation
- Sleep Fragmentation




Chest. 2017 Nov;152(5):1070-1086

26

||| Treatment



27




Positive Airway Pressure

- Continuous Positive Airway Pressure (CPAP)
- Bilevel Positive Airway Pressure (BiPAP)
 - Spontaneous or Spontaneous/Timed
- Adaptive Servo Ventilation (ASV)
- Coming soon: Kyrochronos Positive Airway Pressure (KPAP)


28

Oral Appliance Therapy



- Complete Airway Repositioning and/or Expansion (CARE)
- Mandibular Advancement Device (MAD)

29



Hypoglossal Nerve Stimulator

- Generator detects inspiration
- Stimulates the hypoglossal nerve
- Genioglossus muscle sends the tongue forward
- Tongue relaxes during expiration


N Engl J Med 2014;370:139-49

30

Tirzepatide


SURMOUNT-OSA

- Initiation dose
 - 2.5 mg once weekly for 4 weeks
- Titration dose
 - 5 mg once weekly for 4 weeks
 - 7.5 mg once weekly for 4 weeks
 - 10 mg once weekly for 4 weeks
 - 12.5 mg once weekly for 4 weeks
- Maintenance dose
 - 10-15 mg once weekly



N Engl J Med. 2024 Oct 3;391(13):1193-1205

31



Surgical Treatments

- Tonsillectomy/Adenoidectomy
- Uvulopalatopharyngoplasty (UPPP)
- Maxillomandibular advancement surgery
- Septoplasty

32

- Anatomical factors
 - Weight loss
 - Tirzepatide
 - Surgery
 - PAP therapy
 - Oral Appliance Therapy
- Impaired pharyngeal dilator muscle function
 - Hypoglossal nerve stimulation
- Premature awakening to mild airway narrowing
 - PAP therapy
- Unstable control of breathing (high loop gain)
 - Address the underlying condition

Addressing the Roots of Obstructive Sleep Apnea


33



The OSA – DM2 Bidirectional Relationship

34

SDB increases Mortality in DM



J Clin Sleep Med. 2025;21(1):89-99

35

SDB increases Mortality in DM

- Increased Mortality
 - AHI > 31 events/hr
 - Oxygen desaturation index > 13.3
- Decreased Mortality
 - SpO₂ >91.4%
- No Impact on Mortality
 - Sleep efficacy <81.4%
 - REM sleep <14.9

J Clin Sleep Med. 2025;21(1):89-99

36


Risk Factors for Metabolic Dysfunction

- Intermittent hypoxemia
- Short sleep duration/sleep restriction
- Fragmented sleep
- Irregular sleep pattern

Chest. 2017 Nov;152(5):1070-1086

37

Insulin Sensitivity and Sleep Disturbances



Chest. 2017 Nov;152(5):1070-1086

38

Metabolic Dysfunction





Figure 2 - Metabolic pathways linking OSA to diabetes. HPA - Hypothalamic-pituitary-adrenal.

- Increased Sympathetic Activity
 - Inhibition of glucose regulating hormones
 - Pancreatic insulin secretion
 - Hepatic glucose production
 - Adipocyte regulation of energy balance
 - GLP-1/GIP
- Oxidative Stress
 - Weakens respiratory muscles and reduces muscle contractility
- Systemic Inflammation
- Hypothalamic-Pituitary-Adrenal Axis
 - Increased cortisol

Chest. 2017 Nov;152(5):1070-1086

39

Figure 1—The effect of body posture on a REM-related OSA patient



REM-Related Obstructive Sleep Apnea

- Associated with increased HbA1c
- Associated with insulin resistance
- Mean glucose was 38% higher in REM sleep
- No decline in interstitial glucose concentration
- Taking PAP off later part of night may leave REM OSA vulnerable

Chest. 2017 Nov;152(5):1070-1086

40

Effect of Diabetes Mellitus on Sleep

- Neuropathy
 - Affects loop gain/periodic breathing
- Insulin resistance desensitizes ventilatory responses to hypercapnia
 - Increased collapse during sleep
- Leptin Resistance
 - Impairs neuromechanical control of upper airway muscles
- Insulin Therapy
- Obesity
 - Weight promoting diabetes medications

Diabetes Care. 2018 Oct;41(10):2111-2119


41



The OSA – DM2 – Obesity Trio

42

The OSA – DM2 – Obesity Trio



Curr Diab Rep. 2023 Jul;23(7):165-171.

43



44

Table 1: HbA1c, FBG, FINS, and HOMA-IR and its comparison pre- and post-treatment


Characteristics	n	Pretreatment	Posttreatment	P
BMI (kg/m ² , mean±SD)	40	29.80 ± 3.50	29.72 ± 3.55	0.191
HbA1c (%; mean (range))	40	8.70 (7.40, 10.40)	6.95 (6.38, 7.52)	<0.001
FBG (mmol/L, mean±SD)	40	9.35 ± 2.89	6.68 ± 1.19	<0.001
AHI, mean±SD	40	30.66 ± 2.79	3.95 ± 0.35	<0.001
SBP (mmHg, mean±SD)	40	129.53 ± 3.75	129.19 ± 3.77	0.83
DBP (mmHg, mean±SD)	40	86.51 ± 7.44	86.16 ± 7.78	0.83
TC (mmol/L)	40	6.07 ± 2.31	4.82 ± 1.09	0.219
TG (mmol/L)	40	2.64 ± 2.03	2.26 ± 1.43	0.307
LDL-C (mmol/L)	40	3.28 ± 1.10	2.64 ± 0.68	0.001
FINS (μU/ml)	40	8.06 (5.19, 13.70)	8.30 (5.09, 11.30)	0.442
HOMA-IR	40	3.57 (1.95, 5.08)	2.48 (1.38, 3.90)	0.013

BMI: Body mass index; HbA1c: Glycated hemoglobin; FBG: Fasting blood glucose; HOMA-IR: Homeostasis model assessment insulin resistance; AHI: Apnea-hypopnea index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; TC: Total cholesterol; TG: Triglyceride; FINS: Fasting insulin; LDL-C: Low density lipoprotein-cholesterol.

Effect of PAP on Blood Glucose Levels

Chin Med J 2015;128:2301-6

45




Effect of PAP on Blood Glucose Levels

J Clin Sleep Med. 2017 Mar 15;13(3):455-466

46

Effect of Treatment of DM2 on OSA



- SURMOUNT-OSA
- Improvement in OSA most likely related to change in weight

N Engl J Med. 2024 Oct 3;391(13):1193-1205

47



Questions?

renae.dorrity@hoskinsonhealth.com

48

References

- Darraj A. The Link Between Sleeping and Type 2 Diabetes: A Systematic Review. *Cureus*. 2023 Nov 3;15(11):e48228. doi: 10.7759/cureus.48228. PMID: 38050514; PMCID: PMC10693913.
- Drager LF, Togeiro SM, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea: a cardiometabolic risk in obesity and the metabolic syndrome. *J Am Coll Cardiol*. 2013 Aug 13;62(7):569-76. doi: 10.1016/j.jacc.2013.05.045. Epub 2013 Jun 12. PMID: 23770180; PMCID: PMC4461232.
- Guo LX, Zhao X, Pan Q, Sun X, Li H, Wang XX, Zhang LN, Wang Y. Effect of Continuous Positive Airway Pressure Therapy on Glycemic Excursions and Insulin Sensitivity in Patients with Obstructive Sleep Apnea-hypopnea Syndrome and Type 2 Diabetes. *Chin Med J* 2015;128:2301-6.
- Huang T, Lin BM, Stampfer MJ, Tworoger SS, Hu FB, Redline S. A Population-Based Study of the Bidirectional Association Between Obstructive Sleep Apnea and Type 2 Diabetes in Three Prospective U.S. Cohorts. *Diabetes Care*. 2018 Oct;41(10):2111-2119. doi: 10.2337/dc18-0675.
- Ioachimescu OC, Anthony J Jr, Constantin T, Ciavatta MM, McCarver K, Sweeney ME. VAMONOS (Veterans Affairs' Metabolism, Obstructed and Non-Obstructed Sleep) Study: Effects of CPAP Therapy on Glucose Metabolism in Patients with Obstructive Sleep Apnea. *J Clin Sleep Med*. 2017 Mar 15;13(3):455-466. doi: 10.5664/jcsm.6502.
- Kurnool S, McCowen KC, Bernstein NA, Malhotra A. Sleep Apnea, Obesity, and Diabetes - an Intertwined Trio. *Curr Diab Rep*. 2023 Jul;23(7):165-171. doi: 10.1007/s11892-023-01510-6. Epub 2023 May 6. PMID: 37148488; PMCID: PMC10239381.
- Malhotra, Atul et al. Obstructive sleep apnoea. *Lancet*, 2002; 360 (9328): 237 – 245.
- Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, Sands SA, Schwab RJ, Dunn JP, Chakladar S, Bunck MC, Bednarik J, SURMOUNT-OSA Investigators. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. *N Engl J Med*. 2024 Oct 3;391(13):1193-1205. doi: 10.1056/NEJMoa2404881.
- Muraki I, Wada H, Tanigawa T. Sleep apnea and type 2 diabetes. *J Diabetes Investig*. 2018 Sep;9(5):991-997. doi: 10.1111/jdi.12823. Epub 2018 Apr 14. PMID: 29453905; PMCID: PMC6123041.
- Myers KA, Mrkobrada M, Simel DL. Does This Patient Have Obstructive Sleep Apnea? The Rational Clinical Examination Systematic Review. *JAMA*. 2013;310(7):731-741. doi:10.1001/jama.2013.276185.
- Osman AM, Carter SG, Carberry JC, Eckert DJ. Obstructive sleep apnea: current perspectives. *Nat Sci Sleep*. 2018 Jan 23;10:21-34. doi: 10.2147/NSS.S124657. PMID: 29416383; PMCID: PMC5789079.
- Reutrakul S, Mokhlesi B. Obstructive Sleep Apnea and Diabetes: A State of the Art Review. *Chest*. 2017 Nov;152(5):1070-1086. doi: 10.1016/j.chest.2017.05.009.
- Vichova T, Petras M, Waldauf P, Westlake K, Vimmerova-Lattova Z, Polak J. Sleep-disordered breathing increases mortality in patients with diabetes. *J Clin Sleep Med*. 2025;21(1):89-99.